NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

There were no issues with screening and all of these patients have a terrible prognosis from the start. There is no indication that the patients in this trial were selected for their special ability to survive for long periods of time and statistically that is highly improbable, but moreover, it does not appear to have been anything that a peer review suggested was an issue. To the contrary, it appears that patients with low preselects for long survival, old patients, patients with partial resection, recurred patients, all had their survival extended with statistical significance.

The article you keep pointing to as “peer reviewed” is not peer reviewed. They did not do a study with data. It is clearly labeled “Editorial”, which means it is the opinion of two highly conflicted doctors who did not fully disclose their conflicts. They, surprise, surprise, are connected to the main competitor who appears to be behind pretty much every criticism of this trial, which is to be expected as approval of DCVax-L will substantially affect their business.